ASCO GI 2023 | Targeted treatment for gastric cancer beyond HER2

Nick Pavlakis, PhD, MBBS, FRACP, Royal North Shore Hospital, Sydney, Australia, discusses targeted therapies for gastric cancer beyond HER2, including claudin18.2, the targeting of which was assessed in the Phase III SPOTLIGHT (NCT03504397) trial which evaluated zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, demonstrating a positive result. Patients without targetable alterations have the option of being treated with chemo- and immunotherapy. If such treatment fails, the Phase III INTEGRATE IIa (NCT02773524) trial revealed the efficacy of regorafenib for patients with refractory advanced gastroesophageal cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.